314 related articles for article (PubMed ID: 30401586)
1. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia.
Morsink LM; Walter RB; Ossenkoppele GJ
Blood Rev; 2019 Mar; 34():26-33. PubMed ID: 30401586
[TBL] [Abstract][Full Text] [Related]
2. CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia.
Li Q; Liang C; Xu X; Zhang C; Cao W; Wang M; Jiang Z; Xing H; Yu J
Leuk Lymphoma; 2022 Sep; 63(9):2136-2148. PubMed ID: 35481814
[TBL] [Abstract][Full Text] [Related]
3. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
Willier S; Rothämel P; Hastreiter M; Wilhelm J; Stenger D; Blaeschke F; Rohlfs M; Kaeuferle T; Schmid I; Albert MH; Binder V; Subklewe M; Klein C; Feuchtinger T
Blood; 2021 Feb; 137(8):1037-1049. PubMed ID: 33094319
[TBL] [Abstract][Full Text] [Related]
4. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
[TBL] [Abstract][Full Text] [Related]
5. Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy.
Bill M; Aggerholm A; Kjeldsen E; Roug AS; Hokland P; Nederby L
Br J Haematol; 2019 Mar; 184(5):769-781. PubMed ID: 30520015
[TBL] [Abstract][Full Text] [Related]
6. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome.
Toft-Petersen M; Nederby L; Kjeldsen E; Kerndrup GB; Brown GD; Hokland P; Stidsholt Roug A
Br J Haematol; 2016 Nov; 175(3):393-401. PubMed ID: 27612176
[TBL] [Abstract][Full Text] [Related]
8. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.
Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR
Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800
[TBL] [Abstract][Full Text] [Related]
9. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
Ngai LL; Ma CY; Maguire O; Do AD; Robert A; Logan AC; Griffiths EA; Nemeth MJ; Green C; Pourmohamad T; van Kuijk BJ; Snel AN; Kwidama ZW; Venniker-Punt B; Cooper J; Manz MG; Gjertsen BT; Smit L; Ossenkoppele GJ; Janssen JJWM; Cloos J; Sumiyoshi T
Eur J Haematol; 2021 Sep; 107(3):343-353. PubMed ID: 34053123
[TBL] [Abstract][Full Text] [Related]
10. The CLEC12A receptor marks human basophils: Potential implications for minimal residual disease detection in acute myeloid leukemia.
Toft-Petersen M; Stidsholt Roug A; Plesner T; Ebbesen L; Brown GD; Nederby L
Cytometry B Clin Cytom; 2018 May; 94(3):520-526. PubMed ID: 28718199
[TBL] [Abstract][Full Text] [Related]
11. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
12. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
13. Targeting CLL-1 for acute myeloid leukemia therapy.
Ma H; Padmanabhan IS; Parmar S; Gong Y
J Hematol Oncol; 2019 Apr; 12(1):41. PubMed ID: 31014360
[TBL] [Abstract][Full Text] [Related]
14. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
Mehta NK; Pfluegler M; Meetze K; Li B; Sindel I; Vogt F; Marklin M; Heitmann JS; Kauer J; Osburg L; Zekri L; Bühring HJ; Mueller S; Hörner S; Baeuerle PA; Michaelson JS; Jung G; Salih HR
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288466
[TBL] [Abstract][Full Text] [Related]
15. Antigen Expression Varies Significantly between Molecular Subgroups of Acute Myeloid Leukemia Patients: Clinical Applicability Is Hampered by Establishment of Relevant Cutoffs.
Herborg LL; Nederby L; Brøndum RF; Hansen M; Hokland P; Roug AS
Acta Haematol; 2021; 144(3):275-284. PubMed ID: 33271547
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.
Darwish NH; Sudha T; Godugu K; Elbaz O; Abdelghaffar HA; Hassan EE; Mousa SA
Oncotarget; 2016 Sep; 7(36):57811-57820. PubMed ID: 27506934
[TBL] [Abstract][Full Text] [Related]
17. Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.
Bill M; B van Kooten Niekerk P; S Woll P; Laine Herborg L; Stidsholt Roug A; Hokland P; Nederby L
J Cell Mol Med; 2018 Apr; 22(4):2311-2318. PubMed ID: 29411522
[TBL] [Abstract][Full Text] [Related]
18. An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia.
Zheng B; Yu SF; Del Rosario G; Leong SR; Lee GY; Vij R; Chiu C; Liang WC; Wu Y; Chalouni C; Sadowsky J; Clark V; Hendricks A; Poon KA; Chu W; Pillow T; Schutten MM; Flygare J; Polson AG
Clin Cancer Res; 2019 Feb; 25(4):1358-1368. PubMed ID: 29959143
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
Tashiro H; Sauer T; Shum T; Parikh K; Mamonkin M; Omer B; Rouce RH; Lulla P; Rooney CM; Gottschalk S; Brenner MK
Mol Ther; 2017 Sep; 25(9):2202-2213. PubMed ID: 28676343
[TBL] [Abstract][Full Text] [Related]
20. Cooperative CAR targeting to selectively eliminate AML and minimize escape.
Haubner S; Mansilla-Soto J; Nataraj S; Kogel F; Chang Q; de Stanchina E; Lopez M; Ng MR; Fraser K; Subklewe M; Park JH; Wang X; Rivière I; Sadelain M
Cancer Cell; 2023 Nov; 41(11):1871-1891.e6. PubMed ID: 37802054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
